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Objective: Progression of carotid intima-media thickness (CIMT) is a surrogate indicator for 
the early stages of atherosclerosis.
Methods: The study investigated relationships between baseline lipoprotein cholesterol, 
triglyceride (TG), and apolipoprotein (Apo) B levels assessed with density gradient 
ultracentrifugation (DGU) and progression of posterior wall common CIMT in men (45–75 years 
of age) and women (55–74 years of age) in the control arm of a clinical trial. Participants had 
baseline posterior wall CIMT 0.7–2.0 mm, without significant stenosis. CIMT was assessed using 
B-mode ultrasound at baseline, and 12 and ∼18 months. A DGU cholesterol panel that assessed 
the major lipoprotein classes and subclasses, plus triglycerides, lipoprotein (a) cholesterol, 
low-density lipoprotein (LDL) peak time (inversely related to LDL particle density), and Apo 
B were performed on fasting baseline samples. Apo B was also measured using an enzyme 
linked immunosorbent assay.
Results: Baseline CIMT was inversely associated (P , 0.001) with CIMT progression. After 
adjustment for baseline CIMT, significant predictors of posterior wall CIMT progression in linear 
regression analyses included LDL peak time (inverse, P = 0.045), total high-density lipoprotein 
cholesterol (HDL-C) (inverse, P = 0.001), HDL2-C (inverse, P = 0.005), HDL3-C (inverse, 
P = 0.003), very low-density lipoprotein (VLDL)-C (P = 0.037), and VLDL1+2-C (P = 0.016).
Conclusion: These data indicate that DGU-derived indicators of the “atherogenic lipo-
protein phenotype,” including increased TG-rich lipoprotein cholesterol, lower HDL-C and 
HDL-C subfractions, and a greater proportion of LDL-C carried by more dense LDL particles, 
are associated with CIMT progression in men and women at moderate risk for coronary heart 
disease.
Keywords: carotid intima media thickness, density gradient ultracentrifugation, coronary heart 
disease risk, lipids, atherosclerosis, lipoprotein subfractions
Introduction
Carotid artery intima-media thickness (CIMT) is a surrogate measure of atherosclerosis 
that has been shown to correlate with risk factors for atherosclerotic cardiovascular 
disease.1–6 In a recent analysis of patients at moderate risk for coronary heart disease 
(CHD), non-lipid CHD risk factors were either unrelated to, or weakly associated with, 
CIMT progression, whereas several indicators of lipoprotein metabolism were signifi-
cantly associated with CIMT progression.5 The strongest individual predictors of CIMT 
progression were lower baseline CIMT and increased concentrations of triglycerides 
(TG), non-high-density lipoprotein cholesterol (HDL-C), and apolipoprotein (Apo) B.5 
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These relationships were based on a standard lipid panel 
performed using automated chemistry analyzers, including 
calculation of LDL-C using the Friedewald equation.7
While elevated low-density lipoprotein (LDL)-C and 
non-HDL-C and reduced HDL-C concentrations are acknowl-
edged to be primary CHD risk factors,8 the clinical signifi-
cance of all lipoprotein classes and subclasses is not fully 
understood. There are several methods available to measure 
lipoprotein subfractions including Vertical Auto Profile® 
(VAP; Atherotech Inc, Birmingham, AL), nuclear magnetic 
resonance, and gradient and modified nongradient gel elec-
trophoresis.9 The VAP test directly measures cholesterol 
concentrations of the lipoprotein classes and subclasses after 
they are separated in a density gradient, using vertical spin 
ultracentrifugation.9 This study evaluated the associations 
between density   gradient ultracentrifugation (DGU)-derived 
lipoprotein class and subclass cholesterol concentrations, 
derived Apo B and the rate of CIMT progression among 
the subjects at moderate CHD risk based on having CIMT 
above the US population median of 0.7 mm plus at least one 
major CHD risk factor or LDL-C $130 mg/dL.5,8
Methods
Study design
The results described herein are from a sub-analysis of 
  subjects from the control arm of a double-blind, randomized, 
clinical trial designed to evaluate the effects on CIMT of 
consumption of pomegranate juice versus a control   beverage 
for ∼18 months.10 Full details of the original study and prior 
subgroup analyses have been previously published.5,10 The 
trial was conducted in accordance with good clinical   practice 
guidelines, and the protocol was approved by   Quorum 
Review Inc, Seattle, WA. Two clinical research sites, Radiant 
Research, Chicago, IL and the University of Texas South-
western Medical Center, Dallas, TX, enrolled subjects in the 
trial. All subjects provided written informed consent prior 
to any protocol-specific procedures, and visited the clinic 
at screening, weeks 0, 13, 26, 38, 52, 65, and once between 
weeks 78 and 90.
Subjects
Participants in the study included men (ages 45–74 years) 
and women (ages 55–74 years) at moderate risk for CHD 
due to at least one of the following: LDL-C $130 mg/dL 
and ,190 mg/dL, low HDL-C (,40 mg/dL), elevated 
blood pressure ($140/90 mmHg), use of medication to treat 
hypertension, or current cigarette smoking (any cigarette 
smoking within the past month). Subjects were required to 
have a baseline posterior wall common CIMT measurement 
of .0.7 mm and ,2.0 mm on either the right or left side, 
but carotid stenosis $50% was exclusionary. Subjects were 
also excluded if they had CHD or a CHD risk equivalent, 
  including diabetes; body mass index (BMI) .40 kg/m2; 
hepatic disease or dysfunction; cancer (except non-melanoma 
skin cancer) in the past two years; human immunodeficiency 
virus; hepatitis B or C; uncontrolled hypertension   (average 
systolic blood pressure $160 mmHg and/or average   diastolic 
blood pressure $100 mmHg); cardiac arrhythmias; untreated 
hypothyroidism; used β-adrenergic blockers, immunosup-
pressants, or estrogen and/or progestin therapy; or recently 
(within 6 weeks prior to screening) used lipid-altering agents 
other than statins.
Carotid ultrasound measurements
Baseline, 12 month, and end of treatment posterior wall 
CIMT was measured following the methods described by 
Mazzone et al.11 Using a high-resolution B-mode carotid 
artery ultrasound with an HDI® 5000 ultrasound system 
(Phillips Medical Systems NA, Bothell, WA) longitudinal 
scans were taken of the blood-intima and media-adventitia 
interfaces of the right and left common carotid arteries, 
along a 1 cm segment proximal to the bifurcation.10 Results 
were based on the averages of values for the right and left 
common carotid arteries. Software was used to ensure that 
all scans were performed in the same artery region. Using 
end-diastolic electrocardiographic gating scans, images were 
digitally recorded and the scans were transmitted to a central 
imaging laboratory where an expert reviewer calculated 
the mean CIMT using automated lumen-intima and media-
adventitia edge detection (Io-QIMT, Synarc-IoDP Medical 
Imaging Research [Synarc, Paris, France]). All scans were 
read by a single reader.
Laboratory measurements
Laboratory measurements were conducted by Atherotech 
Inc (Birmingham, AL) on fasting samples collected at 
screening and/or baseline (average of two samples) and 
frozen at −80°C for up to approximately 7.5 years. DGU 
was used to measure total cholesterol (TC), total LDL-C 
[LDL1+2+3+4-C + lipoprotein (a)-C {Lp(a)-C} + intermediate 
density   lipoprotein (IDL)-C], “real” LDL-C (LDL1+2+3+4-C), 
LDL1+2-C, LDL3+4-C, Lp(a)-C, LDL peak time, IDL-C, total 
HDL-C, HDL2-C, HDL3-C, total VLDL-C, VLDL1+2-C, 
VLDL3-C, TG, and Apo B. Additionally, Apo B concen-
tration was determined using an immunoturbidimetry 
method [Abbott Architect/C8000 instrument and Architect 
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  Apolipoprotein B reagent (REF# 9D93-21)]. Non-HDL-C 
was calculated as TC – HDL-C.8
Statistical analyses
Statistical analyses were generated using SAS version 9.1.3 
(SAS Institute, Cary, NC). Analyses were performed using 
data collected from subjects who had at least one   post-
baseline CIMT measurement and for whom DGU analysis 
results were available. There were no adjustments made for 
multiple comparisons, and P-values ,0.05 were considered 
statistically significant to minimize the chances of a type II 
statistical error. To determine the CIMT   progression rate 
(mm/year), the slope of the least squares regression line for 
CIMT on time was calculated for each subject. For subjects 
who dropped out of the study prior to the final measurement, 
the progression rate at month 12 was carried forward. Tertile 
groups were identified according to CIMT progression rate. 
Chi-square tests (categorical variables) and multivariate 
regression models, with the characteristic as the   dependent 
variable and tertile group as the independent variable 
(continuous variables), were used to assess differences 
in baseline parameters across tertiles. For all models, 
assumptions of normality of residuals were investigated, and 
for models where it was determined that the distribution was 
not approximated by a normal curve, values for independent 
and/or dependent variables were ranked prior to the final 
analysis (equivalent to a non-parametric analysis). To further 
assess the relationships between lipoprotein lipid and Apo B 
values and CIMT progression rates, multivariate models that 
also contained the baseline CIMT value were generated to 
produce adjusted regression coefficients. Sensitivity analyses 
were also completed to assess possible confounding or effect 
modification (interaction) by several factors including age 
(median split), sex, ethnicity (non-Hispanic white and other), 
and use of lipid-altering agent(s). For these analyses, each 
model contained terms for baseline CIMT, the predictor 
  variable, the potential effect modifier variable, and an 
interaction term (predictor x effect modifier variable).
Results
Study population
The original study randomized 383 subjects to either pome-
granate juice (n = 192) or control (n = 191) groups. The results 
herein are from 110 subjects in the control arm who had at 
least one post-baseline posterior wall CIMT measurement 
and for whom DGU analyses results were available. Mean 
baseline ± standard error of the mean (SEM) baseline, 
12 month, and end of study posterior wall CIMT values were 
0.78 ± 0.01, 0.79 ± 0.01, 0.78 ± 0.01 mm, respectively. The 
mean progression rate in the control group at the end of the 
trial was 0.0070 ± 0.0034 mm/year, respectively.
Subject characteristics according  
to tertiles of CIMT progression
Demographic and baseline clinical characteristics of the 
subjects according to tertiles of posterior wall CIMT progres-
sion at the end of the treatment period are shown in Table 1. 
Univariate analyses for CIMT progression as an ordinal 
(tertile) variable yielded a significant trend for increasing 
CIMT   progression tertile with greater concentrations of fast-
ing glucose (P = 0.006) and a significant trend for less CIMT 
progression higher baseline CIMT (P , 0.001). A significant 
difference among tertiles was also shown for lipid-altering 
medication use (P = 0.032), however there was no clear pat-
tern, as the greatest numbers of subjects taking lipid-altering 
medications (primarily statins) were in the lowest and highest 
tertiles of CIMT progression. Analyses completed for the 
subset of subjects who did not use lipid-altering medications 
yielded parameter estimates that were not materially different 
from those in the entire sample (data not shown).
Baseline DGU lipids and Apo B measurements accord-
ing to tertiles of posterior wall CIMT progression at the end 
of the treatment period are shown in Table 2. Significant 
relationships were detected for increasing CIMT progression 
tertile with greater concentrations of  LDL3+4-C (P = 0.008), 
non-HDL-C (P = 0.028), TG (P , 0.001), Apo B measured 
by DGU (P = 0.005), and Apo B measured by immunoassay 
(P = 0.002). A significant relationship for lower LDL peak 
time (P = 0.001) with increasing CIMT progression tertile 
was also shown. While there were statistically significant 
P-values for HDL2-C (P = 0.028), total VLDL-C (P = 0.010), 
VLDL1+2-C (P = 0.002), and VLDL3-C (P = 0.022), the 
  relationships did not monotonically increase or decrease 
across CIMT progression tertiles for these variables.
Predictors of CIMT progression  
as a continuous variable
Linear regression analyses for lipoprotein lipid and Apo 
B parameters with posterior wall CIMT progression rate 
(mm/year) as the dependent variable, adjusted for baseline 
CIMT, are shown in Table 3. Statistically significant and near-
significant predictors of the posterior wall CIMT   progression 
rate included LDL peak time (P = 0.045), HDL-C (P = 0.001), 
HDL2-C (P = 0.005), HDL3-C (P = 0.003), VLDL-C 
(P = 0.037), VLDL1+2-C (P = 0.016), VLDL3-C (P = 0.056), 
and TG (P = 0.079). Sensitivity analyses   evaluating age, 
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sex, or ethnicity as confounders or effect modifiers yielded 
parameter estimates that were not materially different from 
those in the entire sample (data not shown).
Discussion
Numerous previous investigations have examined the cross-
sectional relationships between cardiovascular disease risk 
markers and CIMT, however relatively few have evaluated 
predictors of CIMT progression rate.5,12,13 As previously 
reported in this population of subjects at moderate CHD 
risk,5 baseline CIMT was a strong inverse predictor of 
posterior wall CIMT progression, but non-lipid CHD risk 
factors such as blood pressure, age, and body mass index 
were not significantly associated with CIMT progression. 
Among lipoprotein-related variables, the strongest predic-
tors of CIMT progression were higher levels of VLDL-C 
and VLDL1+2-C, reduced levels of HDL-C and cholesterol 
carried by HDL subfractions (HDL2-C and HDL3-C), and 
higher LDL peak time (an indicator of greater average LDL 
density). Thus, the “atherogenic lipoprotein phenotype,”8 
also sometimes referred to as the “lipid triad” of elevated TG, 
reduced HDL-C and a predominance of small, dense LDL 
particles was more closely associated with CIMT progression 
in the present study than other indicators of atherosclerosis 
risk such as LDL-C, non-HDL-C, and Apo B.
It should be noted that while CIMT is a surrogate marker 
for the early stages of atherosclerosis, variables that are 
related to the initiation and progression of early atheroscle-
rosis may not always be the best predictors of atherosclerotic 
cardiovascular disease event risk. Cardiovascular events 
result from processes that involve not only atherosclerosis, 
but also inflammation, thrombosis, and plaque instability.14 
Table 1 Baseline demographic and clinical characteristics of subjects according to tertiles of posterior wall common carotid artery 
intima media thickness progression
Parameter CIMT progression  
,-0.0035 mm (n = 36)
CIMT progression −0.0035  
and ,0.0214 mm (n = 37)
CIMT progression  
$0.0214 mm (n = 37)
P-valuea
Mean (SEM)
Age, years 61.0 (8.8) 60.4 (8.3) 60.8 (6.7) 0.790b
BMI, kg/m2 27.5 (4.9) 29.3 (3.4) 29.1 (4.9) 0.136
Systolic BP, mmHg 131.1 (15.7) 127.8 (17.1) 130.8 (21.6) 0.955
Diastolic BP, mmHg 70.5 (12.3) 70.7 (9.3) 72.2 (8.9) 0.480
Fasting glucose, mg/dL 92.1 (8.2) 95.0 (9.0) 97.7 (9.2) 0.006b
Vitamin D (25-OH), ng/mL 19.4 (12.6, 29.7) 19.1 (13.7, 26.3) 23.5 (16.7, 31.4) 0.150b
Baseline CIMT, mm 0.84 (0.11) 0.75 (0.07) 0.73 (0.06) ,0.001b
Framingham 10-yr riskc 7.7 (5.9) 7.8 (4.9) 9.8 (5.9) 0.063b
Number (%)
Men 18 (50.0) 23 (62.2) 21 (56.8) 0.577
Age intervals 0.573
 # 64 years 22 (61.1) 24 (64.9) 26 (70.3)
 $ 65 years 14 (38.9) 13 (35.1) 11 (29.7)
Race/ethnicity 0.404
  White 21 (58.3) 27 (73.0) 25 (67.6)
  Black 10 (27.8) 7 (18.9) 9 (24.3)
  Asian 2 (5.6) 3 (8.1) 1 (2.7)
  Hispanic/latino 1 (2.8) 0 (0.0) 2 (5.4)
BMI $ 30 kg/m2 10 (27.8) 15 (40.5) 15 (40.5) 0.426
Medication use
  Antihypertensive 14 (38.9) 7 (18.9) 14 (37.8) 0.117
  Aspirin 10 (27.8) 5 (13.5) 8 (21.6) 0.323
  Lipid-alteringd 10 (27.8) 2 (5.4) 9 (24.3) 0.032
Major CHD risk factor
  Smoker 5 (13.9) 7 (18.9) 8 (21.6) 0.686
    BP $ 140/90 mmHg or use  
of antihypertensive agents
20 (55.6) 16 (43.2) 20 (54.1) 0.515
  HDL-C , 40 mg/dL 18 (50.0) 21 (56.8) 27 (73.0) 0.119
  Family history of CHD 4 (11.1) 1 (2.7) 1 (2.7) 0.190
Notes: aP-values for continuous variables were for the slope (test for trend) derived by linear regression analysis, and by chi-square test for categorical values; bvalues were not 
normally distributed, and were ranked prior to the final analysis; c10-year % risk of a CHD event; dof the 24 subjects taking lipid-altering medications, 17 were on a statin.
Abbreviations: BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CIMT, carotid artery intima media thickness; HDL-C, high-density lipoprotein 
cholesterol; SEM, standard error of the mean.
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atherogenic, and that VLDL-C is a strong correlate of TG-rich 
remnant particles.8 Thus, non-HDL-C is a better indicator of 
the total burden of cholesterol carried by atherogenic lipo-
proteins (“real” LDL + IDL + Lp(a) + VLDL + chylomicron 
remnants).
Others have suggested that the superiority of   non-
HDL-C does not result from the atherogenicity of TG-rich 
lipoprotein remnants, but instead reflects the relationship 
between non-HDL-C and the number of circulating LDL 
particles.22,23 They point out that approximately 90% of Apo 
B is found in LDL particles, whether or not an individual 
has hypertriglyceridemia. In those with an elevated TG 
concentration, the average LDL particle size is typically 
smaller, and thus the LDL particle concentration is often 
higher in such individuals than would be predicted based 
on the level of LDL-C.
The present results cannot resolve this controversy, 
but can be interpreted as consistent with a role for TG-rich 
lipoproteins in early atherogenesis since VLDL-C and 
VLDL1+2-C concentrations were more strongly associated with 
CIMT progression than levels of LDL-C or Apo B. However, 
caution is warranted since elevated levels of VLDL-C are 
generally associated with other lipoprotein abnormalities 
including increased levels of TG; a   predominance of small, 
Table 2 Baseline density gradient ultracentrifugation lipid measurements according to tertiles of posterior wall carotid intima media 
thickness progression
Parameter (mg/dL except LDL  
peak time which is seconds)
CIMT progression  
,-0.0035 mm (n = 36)
CIMT progression -0.0035  
and ,0.0214 mm (n = 37)
CIMT progression  
$0.0214 mm (n = 37)
P-valuea
Mean (SEM) or median (IQL)
TC 156.3 (4.6) 158.7 (4.8) 165.8 (5.7) 0.181
Total LDL-Cb 97.2 (3.6) 99.4 (3.7) 106.2 (4.5) 0.107
“Real” LDL-Cb 78.8 (3.6) 80.7 (3.6) 86.3 (4.0) 0.156
LDL1+2-C 29.9 (19.1, 39.4) 30.2 (17.7, 38.2) 24.2 (17.5, 32.6) 0.115c
LDL3+4-C 47.7 (3.2) 49.5 (2.4) 59.3 (3.5) 0.008
Lp(a)-C 4.0 (3.0, 8.5) 5.0 (4.0, 7.0) 6.0 (4.0, 8.0) 0.301c
LDL peak time 115.6 (0.6) 114.6 (0.7) 112.5 (0.6) 0.001
IDL-C 12.0 (10.0, 14.0) 10.0 (10.0, 15.0) 12.0 (10.0, 17.0) 0.502c
Total HDL-C 39.0 (1.8) 37.7 (1.7) 34.9 (1.7) 0.095
HDL2-C 8.5 (6.0, 12.0) 9.0 (5.0, 11.0) 7.0 (6.0, 9.0) 0.028c
HDL3-C 29.5 (1.3) 29.1 (1.1) 27.3 (1.2) 0.188
Total VLDL-C 19.0 (15.0, 23.5) 18.0 (15.0, 23.0) 23.0 (18.0, 29.0) 0.010c
VLDL1+2-C 7.4 (5.5, 9.6) 6.8 (6.0, 9.6) 9.9 (7.3, 14.6) 0.002c
VLDL3-C 11.5 (10.0, 13.5) 11.0 (10.0, 13.0) 13.0 (11.0, 16.0) 0.022c
Non-HDL-C 117.2 (4.0) 121.0 (4.2) 130.9 (4.9) 0.028
TG 63.0 (43.0, 87.5) 70.0 (53.0, 101.0) 103.0 (72.0, 127.0) ,0.001c
Apo B DGU 81.5 (2.2) 84.3 (2.2) 91.3 (2.8) 0.005
Apo B immunoassay 79.5 (2.7) 82.0 (2.4) 91.7 (3.0) 0.002
Notes: aP-values derived by linear regression model analysis; btotal LDL-C = LDL1+2+3+4-C+ Lp(a)-C + IDL-C and “Real” LDL-C = LDL1+2+3+4-C; cvalues were not normally 
distributed, and were ranked prior to the final analysis.
Abbreviations: Apo, apolipoprotein; CIMT, carotid intima media thickness; DGU, density gradient ultracentrifugation; HDL-C, high-density lipoprotein cholesterol; IDL-C, 
intermediate density lipoprotein cholesterol; IQL, interquartile limits; LDL-C, low-density lipoprotein cholesterol; Lp(a)-C, cholesterol carried by lipoprotein(a); SEM, 
standard error of the mean; TC, total cholesterol; TG, triglycerides; VLDL-C, very low density lipoprotein cholesterol.
Thus, variables that are only weakly associated or unrelated 
to CIMT progression (such as blood pressure, cigarette 
smoking, and LDL-C in the present investigation) may still 
be highly clinically relevant as predictors of cardiovascular 
event risk and are important targets for therapy. Carotid 
atherosclerosis, and specifically CIMT, has been shown to 
be highly heritable.15,16 Thus, differences in relationships 
between risk factors and CIMT may be influenced by 
genetics. Several genetic variants for carotid atherosclerosis 
have been identified, including Apo E genotype and angio-
tensin converting enzyme and methylene tetrahydrofolate 
reductase polymorphisms, but larger studies are needed to 
confirm their associations with CIMT and CIMT progression 
rates.16 To date, the examinations of polymorphic associa-
tions have primarily focused on the presence of carotid ath-
erosclerosis, and not on changes in CIMT over time.
Population studies have consistently shown that non-
HDL-C is a stronger correlate of CHD event risk than LDL-C 
in those with and without hypertriglyceridemia.17–21 Inves-
tigators have expressed differing views on the explanation 
for the superiority of non-HDL-C. The view expressed in the 
National Cholesterol Education Program Adult Treatment 
Panel III report is that remnants of TG-rich lipoproteins 
(remnants of VLDL, IDL, and chylomicron particles) are 
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dense LDL particles; and reduced levels of HDL-C. While 
speculative, it may be true that different lipoprotein particles 
are more important at different stages in the atherothrombotic 
process. For example, remnants of TG-rich lipoproteins may 
be particularly important in the early stages of development 
whereas LDL particles may be more important regarding 
progression to advanced lesions and/or for promoting plaque 
instability. Despite considerable advances in understanding 
the pathophysiology, at present it is unclear whether reducing 
levels of TG-rich lipoprotein cholesterol, in the absence 
of improvements in other lipoprotein parameters, will be 
associated with less progression of atherosclerosis or lower 
cardiovascular event rates.
All LDL particles, independent of size, are likely 
atherogenic, but smaller, more dense LDL particles have 
been proposed to possess enhanced atherogenicity due to 
longer residence time in circulation, greater ease of entry 
into the arterial wall, increased binding to subendothelial 
proteoglycans, and greater susceptibility to oxidative 
modification.24–26 Although studies have shown a link 
between a predominance of small, dense LDL particles 
and atherosclerotic cardiovascular disease,25–32 adjustment 
for the number of LDL particles, as indicated by the 
Apo B or LDL particle concentration, generally attenuates 
the relationship.25,32 Thus, controversy exists regarding 
whether a gradient of atherogenicity exists across Apo B 
containing lipoproteins and, if so, whether the gradient is 
steep enough to have clinical relevance. In the present study 
the sample size was not large enough to allow meaningful 
investigation of the predictive ability of multiple correlated 
variables. Accordingly, it is uncertain whether the association 
between LDL peak time as a continuous variable reflecting 
LDL subclass distribution was associated with greater 
CIMT progression because of a gradient of atherogenicity 
across Apo B-containing lipoprotein particles, or because 
it correlates with other predictive variables such as higher 
levels of TG-rich lipoproteins or reduced HDL-C.
DGU-assessed HDL-C concentration was inversely 
associated with CIMT progression, which agreed with results 
reported previously for traditional HDL-C measurements.5 
The results were similar for total HDL-C and the HDL2-C 
and HDL3-C subfractions. Thus, the present results do not 
support the view that cholesterol carried by the major HDL 
subfractions is superior to total HDL-C concentration for 
predicting CIMT progression.
As demonstrated in a previous examination of these data,5 
there was a significant trend for increasing CIMT progres-
sion tertile with greater concentrations of fasting glucose. 
Several studies have reported an association between fasting 
and postprandial glucose levels and CIMT.33–35 However, it is 
unclear whether the relationship is causal, ie, hyperglycemia 
acting directly on the arterial wall to initiate thickening, or 
whether it is confounded by other cardiovascular risk factors. 
Using the principles of Mendelian randomization, a recent 
analysis demonstrated a significant association between 
a fasting glucose genetic risk score (created by weighing 
the strength of associations of several glucose-associated 
genetic variants) and CIMT, supporting a causal hypothesis.35 
However, this analysis does not preclude the possibility that 
other cardiovascular risk factors may also be associated with 
these genetic polymorphisms.
While use of lipid-altering medications (primarily 
statins) differed significantly across tertiles of CIMT 
progression, there was no clear pattern, with the lowest 
frequency of lipid-altering medication use in the middle 
tertile. In the present study the components of the athero-
genic lipoprotein phenotype including increased choles-
terol carried by TG-rich lipoproteins, lower HDL-C, and 
a predominance of cholesterol carried by more dense LDL 
particles, was associated with CIMT progression. This 
observation suggests that it would be of interest to compare 
Table 3 Linear regression analysis for progression rate (mm/year) 
after adjustment for baseline posterior wall carotid intima media 
thickness
Variable Regression coefficient (SE) P-value
TC 0.0000 (0.0001) 0.842
Total LDL-Ca 0.0001 (0.0001) 0.359
“Real” LDL-Ca 0.0001 (0.0001) 0.451
LDL1+2-C −0.0001 (0.0001) 0.562
LDL3+4-C 0.0001 (0.0001) 0.147
Lp(a)-C 0.0000 (0.0001) 0.601
LDL peak time −0.0002 (0.0001) 0.045
IDL-C 0.0001 (0.0001) 0.557
Total HDL-C −0.0003 (0.0001) 0.001
HDL2-C −0.0003 (0.0001) 0.005
HDL3-C −0.0003 (0.0001) 0.003
Total VLDL-C 0.0002 (0.0001) 0.037
VLDL1+2-C 0.0002 (0.0001) 0.016
VLDL3-C 0.0002 (0.0001) 0.056
Non-HDL-C 0.0001 (0.0001) 0.173
TG 0.0002 (0.0001) 0.079
Apo B DGU 0.0001 (0.0001) 0.133
Apo B immunoassay 0.0002 (0.0001) 0.067
Notes:  aTotal  LDL-C  =  LDL1+2+3+4-C  +  Lp(a)-C  +  IDL-C  and  “Real”  LDL-C  = 
LDL1+2+3+4-C.
Abbreviations: Apo, apolipoprotein; CIMT, carotid intima media thickness; DGU, 
density  gradient  ultracentrifugation;  HDL-C,  high-density  lipoprotein  cholesterol; 
IDL-C, intermediate density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol; Lp(a)-C, cholesterol carried by lipoprotein(a); SE, standard error; TC, total 
cholesterol; TG, triglycerides; VLDL-C, very low density lipoprotein cholesterol.
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the effects of medications that primarily act to reduce TG-
rich lipoproteins, raise HDL-C, and shift the LDL subclass 
distribution, such as fibrates and omega-3 fatty acids, to 
those of statins, which primarily act to reduce LDL-C and 
have smaller effects on TG-rich lipoproteins, HDL-C, and 
LDL subclass distribution. Statin and fibrate treatment have 
each been shown to slow the rate of CIMT progression.36–38 
The authors are not aware of any randomized trial that 
has directly compared a statin with a fibrate or omega-3 
fatty acids to evaluate effects on CIMT progression. In 
one study, where consecutive dyslipidemia patients were 
treated with either a statin or fibrate, fibrate treatment was 
associated with significantly greater CIMT and a steeper 
CIMT-time relationship than statin treatment, and these 
differences were not explained by differences in LDL-C 
concentrations.39 However, such results are difficult to 
interpret because patients treated with fibrates may have 
differed with regard to the dyslipidemia present at the 
time treatment was initiated, thus additional research will 
be required to address this question in patients with the 
atherogenic dyslipidemia phenotype.
Limitations of the present analyses include: (1) limited 
generalizability of the results due to the exclusion of subjects 
with CHD and diabetes, and the restriction of the sample 
to those with baseline CIMT value .0.7 and ,2.0 mm; 
(2) the possibility of type I statistical errors because a 
relatively large number of variables were evaluated; (3) the 
potential for variability in CIMT scanning at the two   clinical 
research sites, although utilization of a single reader at a 
central   location, and the employment of masking software to 
insure replication of the carotid region of interest,10 improved 
the reliability of the measurements; and (4) a relatively short 
follow-up period.
Conclusion
The results from these analyses indicate that higher levels 
of TG-rich lipoprotein cholesterol, lower levels of HDL-C 
and HDL-C subfractions, and a greater proportion of 
LDL-C   carried by more dense LDL particles were each 
associated with CIMT progression in men and women at 
moderate risk for CHD. Notably, these variables were more 
strongly associated with CIMT progression than LDL-C, 
non-HDL-C, and Apo B concentrations, suggesting that the 
atherogenic lipoprotein phenotype, including elevated TG 
(and TG-rich lipoprotein cholesterol), reduced HDL-C and 
a predominance of smaller, more dense LDL particles may 
have an important role in the initiation and progression of 
early atherosclerosis.
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